These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23359016)

  • 1. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.
    Kil LP; de Bruijn MJ; van Hulst JA; Langerak AW; Yuvaraj S; Hendriks RW
    Am J Blood Res; 2013; 3(1):71-83. PubMed ID: 23359016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
    Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
    Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.
    Singh SP; Pillai SY; de Bruijn MJW; Stadhouders R; Corneth OBJ; van den Ham HJ; Muggen A; van IJcken W; Slinger E; Kuil A; Spaargaren M; Kater AP; Langerak AW; Hendriks RW
    Oncotarget; 2017 Sep; 8(42):71981-71995. PubMed ID: 29069762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
    Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
    Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.
    Rip J; de Bruijn MJW; Appelman MK; Pal Singh S; Hendriks RW; Corneth OBJ
    Front Immunol; 2019; 10():95. PubMed ID: 30761150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
    Chirino A; Montoya S; Safronenka A; Taylor J
    Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38137005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
    Shorer Arbel Y; Katz BZ; Gabizon R; Shraga A; Bronstein Y; Kamdjou T; Globerson Levin A; Perry C; Avivi I; London N; Herishanu Y
    Front Oncol; 2021; 11():646971. PubMed ID: 34055615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.
    Tambaro FP; De Novellis D; Wierda WG
    J Exp Pharmacol; 2021; 13():923-935. PubMed ID: 34744463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.
    Robak T; Witkowska M; Smolewski P
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
    St-Pierre F; Ma S
    Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency.
    Pal Singh S; de Bruijn MJW; de Almeida MP; Meijers RWJ; Nitschke L; Langerak AW; Pillai SY; Stadhouders R; Hendriks RW
    Front Immunol; 2018; 9():1996. PubMed ID: 30271400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.